Operating costs (Tables)

12 Months Ended

Dec. 31, 2018

Operating costs

Summary of research and development expenditure

	Year ended December 31,
	2018		2017		2016
		(Euro, in thousands)
Personnel costs	€	(81,352)	€	(59,950)	€	(42,315)
Subcontracting		(197,644)		(123,054)		(65,649)
Disposables and lab fees and premises costs		(25,525)		(22,277)		(20,414)
Other operating expenses		(18,355)		(13,221)		(11,196)
Total R&D expenses	€	(322,875)	€	(218,502)	€	(139,573)

Summary of R&D expenses under alliance and own funded R&D

	Year ended December 31,
	2018		2017		2016
		(Euro, in thousands)
R&D under alliance	€	(134,046)	€	(122,663)	€	(71,980)
Galapagos funded R&D		(188,829)		(95,839)		(67,593)
Total R&D expenses	€	(322,875)	€	(218,502)	€	(139,573)

Summary of research and development expenditure by program

	Year ended December 31,
	2018		2017		2016
	(Euro, in thousands)
Filgotinib program (partnered)	€	(66,138)	€	(53,212)	€	(22,376)
CF program (partnered)		(30,137)		(46,192)		(31,203)
IPF program on GLPG1690 (proprietary)		(72,718)		(16,190)		(7,129)
OA program on GLPG1972 (partnered)		(15,751)		(7,317)		(6,538)
AtD program on MOR106 (partnered)		(14,999)		(8,404)		(3,491)
Other		(123,132)		(87,187)		(68,836)
Total R&D expenses	€	(322,875)	€	(218,502)	€	(139,573)

Summary of general and administrative expenses

	Year ended December 31,
	2018		2017		2016
		(Euro, in thousands)
Personnel costs and directors fees	€	(25,495)	€	(17,756)	€	(15,160)
Other operating expenses		(10,136)		(6,659)		(6,584)
Total general and administrative expenses	€	(35,631)	€	(24,415)	€	(21,744)

Summary of sales and marketing expenses

	Year ended December 31,
	2018		2017		2016
		(Euro, in thousands)
Personnel costs	€	(2,282)	€	(2,156)	€	(1,167)
Other operating expenses		(1,864)		(646)		(618)
Total sales and marketing expenses	€	(4,146)	€	(2,803)	€	(1,785)